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The increasing prevalence of patients with aortic stenosis worldwide highlights a clinical need for 
improved and accurate prediction of clinical outcomes following surgery. We investigated patient 
demographic and cardiovascular magnetic resonance (CMR) characteristics to formulate a dedicated 
risk score estimating long-term survival following surgery. We recruited consecutive patients 
undergoing CMR with gadolinium administration prior to surgical aortic valve replacement from 2003 
to 2016 in two UK centres. The outcome was overall mortality. A total of 250 patients were included 
(68 ± 12 years, male 185 (60%), with pre-operative mean aortic valve area 0.93 ± 0.32cm2, LVEF 
62 ± 17%) and followed for 6.0 ± 3.3 years. Sixty-one deaths occurred, with 10-year mortality of 23.6%. 
Multivariable analysis showed that increasing age (HR 1.04, P = 0.005), use of antiplatelet therapy (HR 
0.54, P = 0.027), presence of infarction or midwall late gadolinium enhancement (HR 1.52 and HR 2.14 
respectively, combined P = 0.12), higher indexed left ventricular stroke volume (HR 0.98, P = 0.043) and 
higher left atrial ejection fraction (HR 0.98, P = 0.083) associated with mortality and developed a risk 
score with good discrimination. This is the first dedicated risk prediction score for patients with aortic 
stenosis undergoing surgical aortic valve replacement providing an individualised estimate for overall 
mortality. This model can help clinicians individualising medical and surgical care.
Trial Registration ClinicalTrials.gov Identifier: NCT00930735 and ClinicalTrials.gov Identifier: 
NCT01755936.
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Aortic valve stenosis (AS) is the most common valvular heart disease in the Western world, characterised by 
progressive narrowing of the  valve1,2 and a prevalence expected to double over the next 20 years as a result of 
an aging  population3. Currently, AS is the most common condition necessitating valve replacement surgery 
worldwide, representing a major source of global morbidity and mortality and poses a substantial burden on 
healthcare  resources4. Despite this, there is currently no dedicated risk score derived specifically for patients 
undergoing surgical aortic valve replacement (SAVR) for estimating long-term mortality to allow clinicians to 
facilitate precision medicine.
At present, both North American and European  guidelines5,6 recommend surgery in symptomatic patients 
with severe AS and sometimes even in asymptomatic patients with evidence of LV decompensation defined usu-
ally as a reduction in LV ejection fraction (LVEF < 50% attributed to AS). However, several studies have shown 
that other more objective parameters of LV decompensation are independently associated with worse short-to-
medium term outcomes, including identification of myocardial fibrosis on  histology7,8 and fibrosis identified via 
late-gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR). Indeed the presence of midwall 
LGE in AS is associated with an adverse prognosis in single  centre9–11, and one multi-centre  study12. However, 
even after successful AVR, mortality remains high and Euroscore II and STS models whilst predicting in-hospital 
and 30-day mortality, they lack the inclusion of myocardial fibrosis in their models which is a known risk factor. 
Furthermore, although individual predictors have already been investigated including LVEF and midwall fibrosis, 
no score is currently available to bring all those parameters together in predicting risk.
In this study we investigated the additional role of LGE-CMR in developing a mortality risk score for patients 
undergoing SAVR in two institutions, and identified predictors of survival following aortic valve replacement.
Methods
Patient population. Consecutive patients with aortic stenosis undergoing LGE-CMR and subsequent 
SAVR were recruited from two large prospective observational registries: the Royal Brompton Hospital of Impe-
rial College, London, UK including patients from 2003–2016 (ClinicalTrials.gov Identifier: NCT00930735, 
June 30th 2009) and the Edinburgh Heart Centre, Royal Infirmary of University of Edinburgh, Edinburgh, UK 
including patients from 2013 to 2016 (ClinicalTrials.gov Identifier: NCT01755936, December 24th 2012). The 
present study is not associated with the objectives of these trials and does not report results associated with or 
generated from these trials. It uses clinical data generated from these trials to investigate the specific objective 
mentioned above. The study was conducted in accordance with the Declaration of Helsinki after local research 
ethics approval and written patient consent.
Data collection. Medical history and demographic characteristics were collected following patient inter-
views and review of the hospital and community records. Coronary artery disease was defined as prior coronary 
revascularization or the presence of significant coronary artery stenosis as assessed by invasive or computed 
tomography coronary angiography by > 50% lumen diameter narrowing.
Cardiovascular magnetic resonance. At the Royal Brompton Hospital, LGE-CMR was undertaken at 
1.5 T (Magnetom Sonata or Avanto, Siemens AG, Erlangen, Germany) while at the Edinburgh Heart Centre a 
3 T Magnetom Verio (Siemens AG, Erlangen, Germany) was used. A standardised protocol was undertaken in 
each centre as described  previously13,14. In brief, after localisers, steady-state free precession sequences were used 
for aortic valve planimetry (two orthogonal coronal views were taken, and then sagittal “valve stack” imaging 
starting at ~ 10 mm below the level valve and extending to ~ 10 mm above the level of the valve), and assess-
ment of biventricular volumes and LV mass. Ten to fifteen minutes after injection of 0.1 mmol/kg of gadolinium 
contrast agent (Gadovist, Schering AG, Berlin, Germany) inversion recovery–prepared spoiled gradient echo 
images were acquired in standard long- and short-axis views to detect areas of LGE.
CMR image analysis. Anonymised images were analysed at the Royal Brompton Core laboratory with 
CMR Tools (Cardiovascular solutions, London, UK)9,14. The severity of aortic stenosis was assessed using vali-
dated CMR-derived planimetry of the aortic valve area (AVA)15, and graded as follows: mild, > 1.5 to 2.5  cm2; 
moderate, 1.5 to 1.0  cm2; and severe, < 1.0  cm2 in accordance with the American College of Cardiology/Ameri-
can Heart Association  guidelines16. Left atrial volumes in systole and diastole were obtained by the biplane area-
length described  previously17 and were used to calculate the EF as follows:
LA ejection fraction = 100×
(
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Clinical endpoint. The endpoint was all-cause mortality. This was confirmed from hospital notes, commu-
nication with primary care and through the Office of National Statistics, where there is compulsory registration 
of all deaths.
Statistical analysis. All statistical analyses were carried out using STATA (14, StataCorp. College Station, 
TX, USA) and R version 3.2. Variables are expressed as mean ± standard deviation (SD), median and interquar-
tile range (IQR) or counts and percentages as appropriate. The follow-up time for each patient was calculated 
from the day of CMR to the date of death or their most recent evaluation. The annual event rate was calculated 
by dividing the number of patients reaching the endpoint by the total follow-up period for that endpoint. The 
cumulative probability for the occurrence of an outcome was estimated using the Kaplan–Meier method.
Missing data. No variable had more than 10% of data missing. Nonetheless, multiple imputation was under-
taken in variables with any missing data as described in Supplementary Material Methods.
Model development. Cox regression was used to model the relationship between the outcome and the 
significant univariate predictors as from previous  studies18–21. The follow-up time for each patient was time from 
the date of CMR to death, the end of study period or last follow-up date. Patients alive at the end of study period 
or who were lost to follow-up were censored. Univariable Cox regression models were fitted for all potential 
predictors, and those significant at the 10% level were considered in multivariable analysis. A higher threshold 
than the conventional 5% was chosen to minimise the possibility of excluding variables that are only significant 
in the presence of others, in line with similar  studies22,23. These predictors were then fitted in a multivariable 
model and the final model was derived using forward selection at the 15% significance level, so that the selection 
process did not start with an overly complicated model, given the relatively small number of events. Backwards 
elimination was also used as a sensitivity analysis. The degree of model overfitting was assessed and adjusted for 
using internal validation  techniques24. The proportional hazards assumption required by the Cox model was 
investigated using Schoenfeld  residuals23.
Model validation. The risk model was validated internally using bootstrap validation (200 bootstrap 
samples) and measures of predictive performance assessing calibration (calibration slope) and discrimination 
(Uno’s C-index) were  calculated25. The calibration slope was used to assess the degree of agreement between the 
observed and predicted risk of mortality and to adjust for potential model overfitting. Specifically, the estimated 
regression coefficients were shrunk by a factor equal to the calibration slope estimated from bootstrapping 
(linear shrinkage factor)26 Calibration was also examined using a calibration plot, by comparing the observed 
and predicted risk of mortality at 10 years in clinically meaningful risk groups (group cut-offs: 0–25, 25–45, 
45–60, and > 60% 10-year risk of mortality). The C-index was used to measure how well the model discriminated 
between patients with high and low risk of  death26.
Ethics approval and consent to participate. UK National Ethics approval from London and Lothian 
were obtained. Institutional Board approval from Edinburgh Royal Infrimary and Royal Brompton Hospital and 
written informed patient consent were obtained.
Consent for publication. No individual patient data shown.
Results
A total of 250 patients (London 211, Edinburgh 39) were included in this study: age 68 ± 12 years, 185 (74%) 
male, aortic valve area = 0.93 ± 0.32  cm2. There were 161 patients with isolated SAVR, while 89 had SAVR and 
CABG. A total of 168 (67%) patients had severe aortic stenosis while 82 (33%) had moderate aortic stenosis. All 
the patients with moderate aortic stenosis had a concomitant CABG.
Coronary artery disease was present in 114 (46%) and 37 (15%) patients had low flow (defined by LV stroke 
volume < 35mls/m2) (Table 1). CMR was performed at a median of 56 days before the operation (range 14–184).
The patients were followed for a mean 6.0 ± 3.3 years. During this time 61 (24.4%) died, and 4 were lost to 
follow-up, having moved abroad and censored at the last time known to be alive. The mortality observed was 
4.8% at year 1, 9.6% at year 3, 12.5% at year 5 and 23.6% at year 10.
Variables with a p-value lower than the 10% significance level were considered in the multivariable analysis, 
in line with the usual established approach for predictive  models23.
These factors (Table 2) included patient demographics (including age, sex), symptomatic status (including 
NYHA classification), prior medical history (including PCI or renal disease), CMR parameters (including LVEF, 
LV End Systolic Volume indexed (LVSVindex), Right Ventricular Ejection Fraction (RVEF), Left Atrial Ejection 
Fraction (LAEF), presence of midwall or infarction gadolinium or pharmacotherapy taken (including Angio-
tensin Converting Enzyme (ACE) inhibitor or Angiotensin Receptor Blockers (ARB); aspirin or clopidogrel). 
Other variables possibly associated with mortality, including sex (Supplementary Material Fig. 1), BSA (body 
surface area), prior CABG, DM (diabetes mellitus) or prior SAVR, were not significant.
The presence of either midwall fibrosis or infarction pattern fibrosis was associated with worse outcome when 
compared to absence of fibrosis (Fig. 1).
The variable selection procedure resulted in a final model with five predictors (Table 3): LVSV index (higher 
LVSV better survival), age (higher age worse survival), use of antiplatelet therapy (aspirin or clopidogrel) prior to 
SAVR (use associated with better survival), LAEF (higher LAEF associated with better survival) and the presence 
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of myocardial scar (midwall or infarction fibrosis, presence of either associated with worse survival). In internal 
validation, the model demonstrated satisfactory predictive performance indicating that all five predictors were 
important. The calibration slope was 0.86 (95% CI = 0.57–1.14), indicating only mild model overfitting, which 
was nonetheless adjusted for in the prediction equation by multiplying the estimated coefficients (which cor-
respond to the HRs in Table 3) by the shrinkage factor of 0.86. The calibration plot (Fig. 2) shows a good agree-
ment between observed and predicted risks of death at 10 years. The model demonstrated good discrimination 
with a C-index of 0.72 (95% CI = 0.66, 0.79) compared to the C-index obtained using Euroscore II (C-index 
0.66; 95% CI = 0.59, 0.73).





death at 10 yrs
)
= 1− (0.8761282)exp (risk score)
Table 1.  Baseline characteristics of patients according to presence or absence of late gadolinium enhancement 
on CMR.
No GAD (n = 113) Midwall GAD (n = 89) Infarction GAD (n = 48)
P-value
Overall
Mean or % Mean or % Mean or % Mean or %
Age 66 ± 13 70 ± 12 69 ± 11 0.136 68 ± 12
Sex/ male 66.4 79.8 81.3 0.043 74
BSA 1.87 ± 0.23 2.02 ± 0.21 1.96 ± 0.21 0.000 1.94 ± 0.23
Weight 77 ± 17 84 ± 14 80 ± 18 0.007 80 ± 16
BMI 26 ± 5 29 ± 5 32 ± 5 0.008 28 ± 14
Known history of CAD 33.6 40.4 83.3 0.000 45.6
DM 20.4 22.5 29.2 0.473 22.8
CABG 7.1 16.9 25 0.007 14
PCI 8 11.2 29.2 0.001 13.2
Hypercholesterolaemia 30.1 31.5 54.2 0.009 35.2
CVA 4.4 5.6 14.6 0.055 6.8
CKD 3.5 5.6 6.3 0.689 4.8
AF 19.5 22.5 18.8 0.828 20.4
Aspirin/ clopidogrel 53.1 60.7 68.8 0.164 58.8
Statin 48.7 47.2 68.8 0.034 52
ACEI/ ARB 39.8 47.2 56.3 0.149 45.6
Aldo antagonist 18.6 15.7 12.5 0.620 16.4
Beta blocker 35.4 29.2 43.8 0.230 34.8
Ca channel blocker 15.9 20.2 18.8 0.724 18
Diuretic 23.9 32.6 31.3 0.352 28.4
Digoxin 15.9 5.6 14.6 0.067 12
Warfarin 16.8 14.6 4.2 0.095 13.6
Amiodarone 5.3 6.7 6.3 0.910 6
Creatinine 85 ± 24 92 ± 22 89 ± 23 0.149 88 ± 23
NYHA > 2 8 20.2 19.1 0.028 14.5
Euroscore II 1.8 ± 1.6 2.8 + 2.2 2.6 + 1.7 0.003 2.3 ± 1.9
LVEF 67 ± 14 59 ± 18 53 ± 17 0.000 62 ± 17
RVEF 70 ± 12 59 ± 12 59 ± 10 0.206 60 ± 12
LVEDV index 85 ± 34 87 ± 32 94 ± 31 0.243 88 ± 32
LVESV index 31 ± 28 40 ± 29 47 ± 27 0.001 37 ± 27
LVSV index 55 ± 17 48 ± 16 47 ± 14 0.007 51 ± 16
LV mass index 92 ± 30 103 ± 30 103 ± 27 0.014 98 ± 30
LV Hypertrophy 69.9 87.6 66.7 0.004 75.6
LA volume index 56 ± 32 55 ± 27 55 ± 22 0.967 56 ± 28
LAEF 40 ± 18 35 ± 17 31 ± 15 0.014 37 ± 17
Low flow state 8 23 16.7 0.011 14.9
AVA 0.94 ± 0.35 0.918 ± 0.25 0.921 ± 0.35 0.884 0.93 ± 0.315
LBBB 8.8 12.4 8.3 0.648 10
For redo surgical AVR 14.3 7.9 8.3 0.281 10.8
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risk score =age in years× 0.03582+ aspirin/clopidogrel× (−0.53552)+midwall LGE× (0.36025)




× (−0.01842)+ LAEF[%] ∗ (−0.01278)
Table 2.  Cox proportional hazard model univariable analysis of potential predictors of mortality following 
SAVR. A stepwise forward selection was used, allowing us to investigate multiple variables. From these we 
identified the six variables showing the strongest prediction which we included in the final model. This model 
showed only mild overfitting which was nonetheless adjusted for. a Per 10-unit increase.
Risk factor HR P value 95% CI
Age 1.060 0.00 1.03–1.08
Euroscore II 1.160 0.00 1.05–1.28
LVSV index 0.960 0.00 0.94–0.98
LVEF 0.980 0.00 0.97–0.99
LAEF 0.970 0.00 0.95–0.98
Low flow state (< 35 ml/m2) 2.750 0.00 1.56–4.84




Midwall enhancement 2.11 1.14–3.92
Infarction enhancement 2.53 1.26–5.06
Antiplatelet use 0.550 0.02 0.33–0.92
Creatinine 1.010 0.06 1.00–1.02
RVEF 0.980 0.09 0.96–1.00
LA volume indexed 1.060 0.10 0.9–1.13
PCI 1.710 0.10 0.91–3.23
NYHA > 2 1.640 0.12 0.88–3.04
ACE I/ ARB II blocker 0.670 0.13 0.40–1.13
LA diastolic  volumea 1.030 0.14 0.99–1.07
LVESV index 1.010 0.15 1.00–1.01
Weight 0.990 0.18 0.97–1.00
BMI 0.970 0.18 0.92–1.02
BSA 0.520 0.22 0.18–1.50
DM 1.410 0.23 0.80–2.47
LV mass index 0.990 0.25 0.99–1.00
Known CAD 1.350 0.25 0.81–2.25
Redo AVR 0.620 0.26 0.26–1.44
Hypertrophy 0.750 0.30 0.43–1.30
AF 1.310 0.35 0.74–2.34
Hypercholesterolaemia 0.780 0.37 0.44–1.35
Beta blocker 1.260 0.38 0.75–2.12
Digoxin 1.380 0.38 0.68–2.80
Known CRF 1.500 0.39 0.60–3.76
LBBB 1.340 0.44 0.63–2.83
Past MI 1.370 0.47 0.59–3.19
Past CABG 1.260 0.49 0.65–2.42
Warfarin 1.230 0.53 0.65–2.32
Aldosterone antagonist 0.820 0.59 0.40–1.67
Valve ring size 0.970 0.63 0.86–1.09
Ca2+ channel blocker 1.180 0.63 0.61–2.28
LVEDV index 1.000 0.69 0.99–1.01
AVA 0.900 0.82 0.38–2.14
Statin 1.040 0.87 0.62–1.75
Amiodarone 0.960 0.94 0.35–2.66
CVA 1.020 0.96 0.41–2.56
Male 1.000 0.99 0.56–1.77
Diuretic 1.000 0.99 0.55–1.79
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Figure 1.  Kaplan–Meier estimator plot of survival in patients with no gadolinium enhancement, midwall 
enhancement and infarction pattern enhancement. This plot indicates significantly worse prognosis in the 
patients with either form of enhancement (midwall or infarction) out to 10 years (log rank P = 0.029). Patients 
with a mixed pattern of LGE were categorized according to the predominant pattern of fibrosis.
Table 3.  Multivariable analysis of the strongest predictors. Multivariable analysis indicating prognostic 
variables.
Multivariable analysis
Risk factor HR P-value 95% CI
LVSV index 0.979 0.043 0.959 0.999
Age 1.043 0.005 1.013 1.073




Midwall LGE 1.520 0.789 2.928
Infarction LGE 2.147 1.035 4.455
LAEF 0.985 0.083 0.969 1.002
Figure 2.  Observed vs predicted risk of mortality for patients following SAVR. The observed (black) vs 
predicted (grey) risk of mortality for patients following SAVR out to 10 years in clinically relevant risk groups is 
shown, indicating good prediction for the model. Number of patients per risk group: 73, 94, 42 and 41 for risk 
groups 1, 2, 3 and 4, respectively.
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 and aspirin/clopidogrel, midwall LGE, and infarction LGE are assigned the value 1 if present or zero if absent.
Discussion
The number of patients with aortic stenosis undergoing SAVR is increasing world-wide, despite of use of TAVR, 
yet there is no dedicated risk stratification tool to enable precision medicine for those patients. This is the first 
dedicated multicentre registry determining a risk score utilising myocardial tissue characterisation by CMR 
and LA function. We confirm the known association of midwall fibrosis with adverse  prognosis9,12 and further 
propose that even after successful SAVR overall mortality is high, emphasising the importance of regular review 
and medical optimisation following surgery.
It is noticeable that our study demonstrated SV, rather than LVEF, to be one of the strong predictors of 
outcome in this cohort of patients with moderate and severe aortic stenosis. This finding is in agreement with 
other studies focusing on this specific population  cohort27,28. Growing literature evidence suggest that in patients 
with aortic stenosis, it is the longitudinal function of the left ventricular myocardium that becomes significantly 
impaired. This pathophysiological process may progress with an apparently preserved LVEF, hence other param-
eters have been used to identify subtle myocardial impairment, including mitral annular plane systolic excursion 
(MAPSE) and global longitudinal strain (GLS)29–31.
Although generic models for predicting survival after open heart surgery exist and are used in clinical practice 
to identify high risk patients, these are not designed specifically for SAVR and importantly are not specific for 
estimating long-term survival. A tool for estimating long-term survival following SAVR is therefore needed to 
enable individualised decisions for patients. We have developed and internally validated a risk score using the 
most significant variables that can be used to identify patients at risk of overall mortality after SAVR. We have 
used a pragmatic cohort of patients undergoing routine guideline-based surgery to ensure our findings are clini-
cally relevant reflecting the routine patient demographics. The aim of this work was not to identify the correct 
surgical “window” for patients with AS, but to identify pre-operative predictors of survival. As such, a model 
looking at overall mortality in patients who have undergone surgical SAVR based on the existing guidelines is 
able to identify patients with a high risk of mortality. High-risk patients may benefit from more frequent medical 
care by physicians and cardiologists. This model will also allow clinicians to consider longer-term outcomes in 
patients, as currently the use of Euroscore II and STS only allows short-term outcome prediction.
One important novel finding is the prognostically beneficial use of antiplatelet therapy. In the UK if patients 
take antiplatelet therapy before surgery this is continued long-term unless anticoagulation is needed. Multivari-
able analysis showed use of antiplatelets was associated with an almost 50% reduction in overall mortality, inde-
pendently of presence or absence of coronary disease. This suggests that patients with AS undergoing SAVR may 
represent a cohort of patients at high vascular risk who might benefit from antiplatelet therapy in the long term. 
As our cohort of patients was elderly and the vast majority received a tissue bioprosthesis (> 90%) we estimate 
that the continuation of aspirin or clopidogrel could also have had an impact in reducing tissue thrombosis and 
hence improve survival.
Clinical implications. We provide a validated score with predictive variables for calculating mortality risk 
out to 10 years. This score can be used, to identify patients at higher risk following the SAVR that could benefit 
from being followed up in the hospital cardiology outpatients or the community more closely. More specifically, 
this score is applicable not only to the patients with severe AS undergoing SAVR but also to the patients with 
moderate AS and co-existent CAD undergoing SAVR and CABG. Importantly, as our model is derived from 
prognostically important risk factors, it subsequently enables early identification of the patients that carry high 
risk of mortality post intervention. We did not compare AVR vs. medical management. Therefore, even if the 
risk might be high, the individual patient might still fare much better with surgery than medical management. 
Therefore, the aim of the score is to facilitate more tailored post-operative management, than act as prohibi-
tive to surgery, or indeed TAVR, as this falls out of the scope and purpose of the model. Furthermore, follow-
ing appropriate validation, this score could be routinely utilised for selecting patients for transcatheter aortic 
valve replacement in preference to the non-specific Euroscore II and STS, although evidence from randomised 
controlled trials would be invaluable in validating this. Finally, our results indicate that use of an antiplatelet at 
the time of CMR is associated with significantly improved mortality. This is a novel finding suggesting SAVR 
patients represent a cohort with high vascular risk, including valve thrombosis, that might benefit from anti-
platelet therapy independently from other comorbidities. This work lends support to this hypothesis and further 
studies will be needed, however, to determine antiplatelet duration.
Study limitations. Even with two centres, referral bias is possible. However, all our patients fulfilled a clini-
cal indication for SAVR and our catchment areas for referrals is large, spanning across the UK. Additionally, the 
period of patient enrolment was different between the two centres that contributed to this study. Moreover, we 
were not able to include an external validation for this work, as we did not have access to a comparable group 
from other institutions with CMR scans dating back to 2003. Nonetheless, internal validation with the boot-
strapping method we used is considered a suitable and robust validation for prediction  models32. Our aim was to 
identify predictors of survival from the time CMR was undertaken, thus we only included information from that 
period. Although some parameters may have changed in subsequently, we feel this change would have diluted 
rather than strengthened any associations seen. Furthermore, no other adverse events, including hospitalisation 
for heart failure, acute coronary syndrome, stroke were evaluated in this study. This is also important as we did 
not show a difference in mortality between men and women, although larger studies might reveal differences in 
cardiac hospitalisations. In addition, as this study started prior to our increased use of T1 mapping and appro-
priate quality  assurance33 or indeed 4D  flow34 thus, we were unable to incorporate such variables. Finally, with 
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an increase in the use of transcatheter aortic valve replacement (TAVR) especially in low- and medium-risk 
 populations35, it is uncertain whether this risk score will be valid in this population, or whether a different risk 
score needs to be designed. However, for the SAVR cohort, this score is robust and internally validated using the 
strongest statistical validation mechanism possible.
Conclusion
In this large prospective registry-based study with the longest follow-up to date, we show that the risk of mortal-
ity in patients following SAVR remains high. We identify that the age of the patient at the time of SAVR, LVSV 
indexed, LAEF, presence of any myocardial fibrosis and use of antiplatelet therapy can be utilised to provide an 
estimate of mortality for such patients through a risk score, and help guide management both before and after 
surgery.
Data availability
All data can be obtained following reasonable request to the corresponding author.
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